Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780626 | 0.89 | SRD5A1 (0.41) | SMN1; SMN2LMNADRD4ROCK1ALDH1A1 | |
| SCHEMBL4019735 | 0.80 | HPGD (0.34) | SMN1; SMN2ROCK1TSHRSRD5A1RIPK1 | |
| SCHEMBL2061755 | 0.78 | BRD4 (0.39) | DRD4ROCK1ALDH1A1 | |
| SCHEMBL8032869 | 0.75 | AVPR1A (0.41) | SMN1; SMN2AVPR1AMEN1KMT2ATSHR | |
| SCHEMBL21061364 | 0.72 | CYP11B2 (0.45) | SMN1; SMN2LMNADRD4AVPR1AALDH1A1 | |
| SCHEMBL5738839 | 0.71 | BRD4 (0.51) | DRD4AVPR1AALDH1A1MEN1KMT2A | |
| SCHEMBL24194048 | 0.70 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNADRD4ROCK1AVPR1A | |
| SCHEMBL1975907 | 0.70 | SRD5A1 (0.48) | DRD4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16207990 | 0.69 | TSHR (0.38) | ALDH1A1TSHRRIPK1GAANOTUM | |
| SCHEMBL432928 | 0.69 | GRM5 (0.43) | LMNAMAPTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-116209662-A | RIP1K inhibitors | 里格尔药品股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220009936-A1 | RIP1K INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-01-13 | — | — | US | disclosed |
| WO-2022005898-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2509981-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Eli Lilly and Company (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | SMN1; SMN2 2836/4885LMNA 3814/4885DRD4 409/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1932/4885LMNA 2114/4885DRD4 4869/4885 |
| US-20220009936-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1932/4885LMNA 2114/4885DRD4 4869/4885 |
| US-11667643-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1932/4885LMNA 2114/4885DRD4 4869/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | SMN1; SMN2 2836/4885LMNA 3814/4885DRD4 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.